Tuesday, February 17, 2009

Merck Sharp & Dohme Ltd Withdraws Its Marketing Authorisation Application For Vorinostat MSD (Vorinostat)

The European Medicines Agency has been notified by Merck Sharp & Dohme Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Vorinostat MSD (Vorinostat), 100 mg hard capsules.

The details can be read here.

No comments: